Evangelos Oikonomou

Oct 1, 2024 | medrxiv.org | Evangelos Oikonomou |Rohan Khera

V.S. is a coinventor of 63/346, 610 and 63/484,426, and a co-founder of Ensight-AI, Inc. E.K.O. is an academic co-founder of Evidence2Health LLC, a co-inventor in patent applications (18/813,882, 17/720,068, 63/619,241, 63/177,117, 63/580,137, 63/606,203, 63/562,335, US11948230B2), has been a consultant for Caristo Diagnostics Ltd and Ensight-AI Inc, and has received royalty fees from technology licensed through the University of Oxford, outside the submitted work.

Aug 26, 2024 | medrxiv.org | Evangelos Oikonomou |Sumukh Vasisht Shankar |Andreas C. Coppi |Harlan M. Krumholz

R.K. is an Associate Editor of JAMA and receives research support, through Yale, from the Blavatnik Foundation, Bristol-Myers Squibb, Novo Nordisk, and BridgeBio. He is a coinventor of U.S. Provisional Patent Applications 63/177,117, 63/428,569, 63/346,610, 63/484,426, 63/508,315, 63/580,137, 63/606,203, 63/562,335, 18/813,882, and a co-founder of Ensight-AI, Inc and Evidence2Health, LLC.

Jul 2, 2024 | jacc.org | Rohan Khera |Evangelos Oikonomou |Girish N. Nadkarni |Jessica Morley

IntroductionArtificial intelligence (AI) is poised to transform every facet of cardiovascular practice and research.

May 8, 2024 | nature.com | Arya Aminorroaya |Lovedeep S Dhingra |Evangelos Oikonomou |Sumukh Vasisht Shankar

AbstractElevated lipoprotein (a) (Lp(a)) is associated with premature atherosclerotic cardiovascular disease. However, fewer than 0.5% of individuals undergo Lp(a) testing, limiting the evaluation and use of novel targeted therapeutics currently under development. Here we describe the development of a machine learning model for targeted screening for elevated Lp(a) (≥150 nmol l−1) in the UK Biobank (N = 456,815), the largest cohort with protocolized Lp(a) testing.

Mar 15, 2024 | medrxiv.org | Evangelos Oikonomou |Lovedeep Singh Dhingra |Arya Aminorroaya |Andreas C. Coppi

R.K. is an Associate Editor of JAMA and receives research support, through Yale, from the Blavatnik Foundation, Bristol-Myers Squibb, Novo Nordisk, and BridgeBio. He is a coinventor of U.S. Provisional Patent Applications 63/177,117, 63/428,569, 63/346,610, 63/484,426, and 63/508,315, and a co-founder of Ensight-AI, Inc. R.K. and E.K.O. are co-founders of Evidence2Health, a health analytics company.